Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Gastrointestinal 22Thoracic 13Breast 10Head & Neck 5Genitourinary 4Sarcoma 3Gynecologic 3Endocrine 3Tumor-Agnostic 2NET 2Dermatologic 2CNS 2Plasma cell 1Other solid neoplasm 1Lymphoid 1

Conditions

Sarcoma, Ewing 1Neurofibrosarcoma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasm, Residual 1Gastrointestinal Stromal Tumors 1

Interventions

Radiotherapy 137Cyclophosphamide 132Temozolomide 116Doxorubicin 99Filgrastim 68Ifosfamide 64Gemcitabine 58Etoposide 55Bevacizumab 51Imatinib Mesylate 50fludarabine phosphate 49Irinotecan 46pembrolizumab 45Peripheral Blood Stem Cell Transplantation 45pazopanib 43Magnetic Resonance Spectroscopy 42Methotrexate 40Carboplatin 40Busulfan 40Vincristine 38Surgical Procedures, Operative 37Nivolumab 37Melphalan 37Cisplatin 36Radiation 34Blood Specimen Collection 33Mycophenolic Acid 31Cyclosporine 31Docetaxel 29Trabectedin 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Liquid Biopsy × Sarcoma × Clear all
NCT06068075 2026-05-05

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD

Dana-Farber Cancer Institute

Phase NA Active not recruiting
340 enrolled
Sarcoma

Sarcoma, Ewing, Neuroectodermal Tumors, Primitive, Peripheral

NCT06515860 2026-01-09

NF1-TED

Boston Children's Hospital

Recruiting
1,000 enrolled
CNSSarcoma

Neurofibromatosis 1, Neurofibroma, Plexiform, Neurofibrosarcoma

NCT05408897 2022-09-21

Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD

Peking University People's Hospital

Recruiting
45 enrolled
GastrointestinalSarcoma

Neoplasm, Residual, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡